World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   2296 records for 356 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusProspective RegistrationMain ID Public TitleDate of Registration
RecruitingNoNCT03259269
Expand New Drugs for TB [endTB]
21/08/2017
Not RecruitingYesCTRI/2017/07/009035
A clinical trial to study the effects of two drugs SAIT101 and Rituximab for treatment in patients with low tumor of follicular lymphoma (cancer of the immune system)
12-07-2017
AuthorisedYesEUCTR2016-004009-15-ES
Clinical trial to compare the benefit and safety of a single infusion of VIS410, the study medicine added to standard TamifluĀ® treatment to that of treatment with TamifluĀ® alone in hospitalized adults with flu infection requiring oxygen support
09/06/2017
RecruitingYesNCT03164044
Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
22/05/2017
RecruitingNoNCT03164070
Study of the Laboratory-based Evaluation of the Degrees of Activity of Osteoarthritis
22/05/2017
RecruitingYesNCT03114631
Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
11/04/2017
Not recruitingYesNCT03104413
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment 04/04/2017
Not recruitingYesNCT03105102
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991
Recruitment statusMain IDPublic titleDate of registration
Not AvailableEUCTR2016-003191-50-DKA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99118/07/2017
Not AvailableEUCTR2016-003191-50-DEA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99120/07/2017
Not AvailableEUCTR2016-003191-50-CZA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99121/07/2017
Not AvailableEUCTR2016-003191-50-PLA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99103/08/2017
Not AvailableEUCTR2016-003191-50-NLA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99108/08/2017
Not AvailableEUCTR2016-003191-50-EEA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99110/08/2017
AuthorisedEUCTR2016-003191-50-ATA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99131/07/2017
AuthorisedEUCTR2016-003191-50-PTA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99121/07/2017
Not AvailableEUCTR2016-003191-50-LVA Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-99125/07/2017
04/04/2017
Not recruitingYesNCT03105128
A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease 04/04/2017
RecruitingYesNCT03104400
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug 04/04/2017
     
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.3 - Version history